ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models

Date

June 21, 2021

Speaker

Aleksandr Pankov, PhD

ORIC Pharmaceuticals

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.